Dr Reddy's LaboratoriesEmerging entrant · LowListed
Zydus LifesciencesDirect supplier · LowListed
Where it fits
Grows proteins in mammalian or microbial cell cultures, purifies them and fills them into vials, syringes and pens - biosimilar copies of off-patent biologics (insulin, trastuzumab, adalimumab, aflibercept, denosumab) and vaccines supplied to UNICEF, Gavi and national programmes.
Why it matters
Over US$200bn of global biologic sales lose exclusivity over the next decade, and biosimilars need far more capital and know-how than small-molecule generics, so fewer competitors share the market. India also makes the majority of the world's vaccine doses (Serum Institute alone is the largest maker by volume) - but most of that value sits in unlisted companies.
Where the value pool sits
Biosimilars earn 20-30% EBITDA margins once scaled, after years of losses on development (~US$100-250m per molecule) and regulatory spend. Vaccines are tender-driven (UNICEF/Gavi pricing) with high volumes and periodic windfalls. Listed exposure is concentrated in Biocon.
Key drivers
Biologic patent expiries (Stelara, Eylea, Prolia/Xgeva, Keytruda later this decade)
FDA moves to simplify biosimilar development (fewer comparative efficacy trials)
Biopharma SHAKTI (₹10,000 Cr, Budget 2026-27)
Vaccine demand from Gavi/UNICEF and new vaccines (HPV, dengue)
Potential bottlenecks
Development cost and time (7-8 years per biosimilar)
US interchangeability and payer access (PBM formularies)
Cold-chain and fill-finish capacity
Investor metrics to watch
Number of commercial biosimilars and market shares by molecule